rs145999145 — PLD3 V232M

Rare missense variant in the lysosomal exonuclease PLD3 that impairs endolysosomal function and amyloid precursor protein processing, associated with approximately doubled late-onset Alzheimer's disease risk in the discovery cohort (OR ~2.10) and a pooled OR of 1.53 in meta-analysis; replication has been inconsistent across large European cohorts.

See your personal result for PLD3

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

PLD3 V232M — A Rare Lysosomal Variant at the Edge of Alzheimer's Genetics

Deep in the endolysosomes of every cortical and hippocampal neuron, a protein called PLD3 (phospholipase D family member 3) acts as a 5′ exonuclease — degrading single-stranded DNA and RNA that accumulates in the acidic lysosomal lumen. This housekeeping role prevents inflammatory nucleic acid signals from leaking into the cytosol and supports the orderly processing of amyloid precursor protein (APP)11 amyloid precursor protein (APP)
APP is cleaved in the endolysosomal compartment; the balance between amyloidogenic (Aβ-producing) and non-amyloidogenic cleavage is influenced by lysosomal function. The rs145999145 variant (c.694G>A, p.Val232Met) substitutes methionine for valine at position 232 and is found in roughly 0.5% of Europeans — rare enough that its population-genetic signal has been difficult to replicate, yet functionally well-characterised as a loss-of-function variant.

The Mechanism

The Val232Met substitution disrupts two interconnected aspects of PLD3 biology. First, Demirev et al. (2019)22 Demirev et al. (2019)
V232M substitution restricts a distinct O-glycosylation of PLD3 and its neuroprotective function. Neurobiology of Disease, 2019 showed that V232M blocks an essential O-glycosylation at threonine 271. This modification is required for normal lysosomal trafficking; without it, PLD3 mislocalises, lysosomes enlarge abnormally, and the mutant protein loses its ability to reduce ER stress and neuronal apoptosis in Drosophila Alzheimer's models. Second, Nackenoff et al. (2021)33 Nackenoff et al. (2021)
PLoS Genetics demonstrated directly that the V232M variant protein "lacked PLD activity" in isolated lysosomal fraction assays, confirming a genuine enzymatic loss-of-function. In 531 ROS/MAP participants, higher prefrontal PLD3 expression correlated with lower amyloid plaque burden and slower global cognitive decline (p=0.02), suggesting PLD3 activity has measurable consequences for AD trajectory.

The downstream impact on neuronal circuits was defined by Yuan et al. (2022) in Nature44 Yuan et al. (2022) in Nature
PLD3 affects axonal spheroids and network defects in Alzheimer's disease. PLD3 accumulates in plaque-associated axonal spheroids — dystrophic axon swellings that cluster around amyloid plaques — and drives the formation of enlarged endolysosomal vesicles within them. These oversized spheroids act as electrical current sinks, producing action-potential conduction blockades proportional to their size. CRISPR deletion of PLD3 in mouse AD models reduced spheroid volume and restored axonal conduction nearly to wild-type levels, demonstrating that PLD3 dysfunction contributes to network failure through a mechanism independent of amyloid burden alone.

The Evidence

Cruchaga et al. (2013) in Nature55 Cruchaga et al. (2013) in Nature
whole-exome sequencing of 14 AD families plus validation in 11,354 European cases and controls identified V232M as doubling AD risk (OR 2.10, 95% CI 1.47–2.99, p=2.93×10⁻⁵). The variant segregated with disease in two independent families and showed gene-level burden across all PLD3 coding variants (European OR 2.75; African American OR 5.48).

However, three replication letters published simultaneously in Nature in 2015 challenged these findings. Lambert et al. (PMID 25832408)66 Lambert et al. (PMID 25832408) and parallel studies in Danish, Spanish, and German cohorts (PMIDs 25832410, 25832411) found no significant association for V232M in large French and multi-European LOAD samples. A European early-onset AD consortium (PMID 26411346; N=2,735) similarly found no enrichment. The V232M variant was consequently reclassified in ClinVar to uncertain significance.

A meta-analysis by Zhang et al. (2016)77 meta-analysis by Zhang et al. (2016)
~40,000 subjects across all available datasets arrived at a pooled OR of 1.53, smaller than the discovery estimate but still above unity. The most likely explanation for the instability is statistical: with a carrier frequency of ~0.5–1% and an OR of ~1.5–2, reliably detecting this signal requires tens of thousands of participants — the replication cohorts of 2,000–4,000 each were simply underpowered.

The evidence level is rated moderate: the functional data are consistent and mechanistically compelling, but the population-genetic replication is incomplete and the variant is classified as uncertain significance in ClinVar.

Practical Actions

For carriers of V232M, the relevant lever is the endolysosomal pathway. Aerobic exercise activates TFEB88 TFEB
transcription factor EB — the master regulator of lysosomal biogenesis; activated by aerobic exercise via AMPK signalling, which drives synthesis of new, functional lysosomes and partially compensates for the endolysosomal deficit. Sleep quality directly affects glymphatic Aβ clearance — a functionally distinct but complementary route for amyloid removal. Plasma p-tau217 is now a validated blood test for preclinical amyloid accumulation and provides an evidence-based monitoring entry point.

Interactions

APOE ε4 (rs429358) is the dominant genetic risk factor for late-onset AD and operates through partially overlapping mechanisms — disrupting endolysosomal lipid trafficking and reducing microglial amyloid clearance. Carriers of both V232M and APOE ε4 face compounding dysfunction at the endolysosomal level that has not been formally quantified but is mechanistically plausible. TREM2 rare variants (including rs75932628 R47H) converge on microglial lysosomal function and represent a second interaction of interest. ABCA7 variants (rs113809142) also affect endolysosomal lipid transport and amyloid processing in the same compartment.

Genotype Interpretations

What each possible genotype means for this variant.

GG Wild-Type Normal

No PLD3 V232M — standard lysosomal PLD3 function, no elevated Alzheimer's risk from this variant

You carry two copies of the common G allele at rs145999145, encoding the ancestral valine at position 232 of PLD3. Your PLD3 enzyme retains full O-glycosylation at T271, traffics normally to lysosomes, and maintains baseline capacity to suppress amyloidogenic APP processing. About 99.1% of people worldwide share this genotype. This variant does not contribute to your Alzheimer's disease risk.

AG V232M Carrier High Risk

One copy of PLD3 V232M — pooled meta-analytic OR 1.53 for late-onset Alzheimer's disease

The mechanistic evidence for V232M causing lysosomal dysfunction is consistent across independent labs. The V232M protein mislocalises due to impaired O-glycosylation at T271, accumulates in enlarged axonal spheroids near amyloid plaques, and worsens endolysosomal vesicle buildup that blocks axonal conduction. In 531 ROS/MAP brain donors, higher PLD3 expression correlated with lower amyloid plaque burden and slower cognitive decline (p=0.02) — consistent with V232M's loss of function contributing to worse disease trajectory.

The uncertain significance classification reflects the population-genetic inconsistency more than the functional data. For a carrier at 0.5–1% frequency, cohorts of 2,000–4,000 are substantially underpowered to detect an OR of 1.5. The pooled meta-analytic OR of 1.53 in ~40,000 subjects is the most reliable epidemiological estimate available.

Clinical significance should be interpreted in context: alongside APOE ε4 status, family history, and modifiable risk factors, V232M represents a meaningful signal warranting earlier surveillance — not a single high-penetrance mutation requiring urgent intervention.

AA Homozygous V232M High Risk

Two copies of PLD3 V232M — extremely rare; complete absence of wild-type PLD3 function

No published case series specifically characterises AA homozygotes at rs145999145. The expected phenotypic severity can be inferred from the functional data: V232M lacks enzymatic activity, disrupts O-glycosylation-dependent lysosomal trafficking, and causes enlarged endolysosomal vesicles in axonal spheroids. With no wild-type copy to compensate, neuronal endolysosomal homeostasis would be more severely compromised across the lifespan.

Clinical guidance for this extremely rare genotype should come from a specialist familiar with genetic Alzheimer's risk assessment. Plasma and imaging biomarkers provide the most actionable information for surveillance and possible early intervention trial eligibility.